The EPO published EP4186972A1 on March 25, 2026, covering controllable transcription technology. Applicant is Cambridge Enterprise Limited with inventors Vallier, Kotter, Pawlowski, Bertero, and Ortmann. The patent is classified under C12N 5/0735 (stem cells) and C12N 15/86 (gene therapy vectors), designated across all 39 EPO member states including Germany, France, UK, Italy, Spain, Netherlands, and others.

This is a patent publication notice rather than a regulatory compliance requirement. Entities conducting research in transcription control, gene therapy, or stem cell technologies should review the claims to assess potential freedom-to-operate implications. The patent does not impose obligations but grants exclusive rights that may affect competitive R&D strategies in the biotechnology and pharmaceutical sectors.